For cisplatin ineligible patients with locally advanced head and neck cancer, would you consider RT + immunotherapy rather than RT + cetuximab?

No. While the cited GORTEC trial showed pembrolizumab was no worse than cetuximab, the results from HN004 showed a significant reduction in PFS in the durvalumab arm. This plus emerging data from the lab of @Dr. First Last (Darragh et al., PMID 36385142) showing that elective nodal radiation signifi...